Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis

INTRODUCTION: Evidence supports the clinical benefits of early aggressive biologic treatment in patients with rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), but the cost-effectiveness of early intervention with or...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Dipen, Shelbaya, Ahmed, Cheung, Raymond, Aggarwal, Jyoti, Park, Sang Hee, Coindreau, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822985/
https://www.ncbi.nlm.nih.gov/pubmed/31148057
http://dx.doi.org/10.1007/s12325-019-00986-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822985/
https://www.ncbi.nlm.nih.gov/pubmed/31148057
http://dx.doi.org/10.1007/s12325-019-00986-7

Ejemplares similares